The goal for STAR-0215 is to provide the most patient-friendly preventative treatment option for people living with HAE. Lead program STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every three months or longer. This model informs our plans for the Phase 1a trial, which aims to evaluate safety, tolerability, demonstrate inhibition of plasma kallikrein activity, and establish the prolonged half-life of STAR-0215." "Pharmacokinetic modeling suggests that STAR-0215 could be effective at inhibiting plasma kallikrein and has the potential to prevent HAE attacks with subcutaneous administration with a self-injectable device dosed once every three-months or longer. Milne, Ph.D., Chief Executive Officer of Astria. We expect initial results by year end," said Jill C. "We are looking forward to advancing STAR-0215 into the clinic this year with the Phase 1a trial, which we plan to initiate shortly after our anticipated mid-year IND filing. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended Maand provided a corporate update. BOSTON, May 12, 2022-( BUSINESS WIRE)- Astria Therapeutics, Inc.
0 kommentar(er)
